17 August 2025 : Clinical Research
Evaluation of Inflammatory Biomarkers in Parotid Tumors
Aykut Ikinciogullari
ABCDEF 1*, Burak Hazir ABCDEF 1, Erdem Aggunlu ABCDEF 1, Mustafa Colak ACDEF 1, Serdar Ensari ADEF 1, Haci Huseyin Dere ADEF 1
DOI: 10.12659/MSM.947334
Med Sci Monit 2025; 31:e947334
Table 3 Comparison of inflammatory biomarkers NLR, PLR, SII, and SIRI between benign and malignant tumors.
| NLR (mean±SD, median) | PLR (mean±SD, median) | SII (mean±SD, median) | SIRI (mean±SD, median) | |
|---|---|---|---|---|
| Benign | 2.24±0.96, 2.04 | 119.64±40.81, 112.9 | 562.34±250.64, 506.10 | 1.06±0.62, 0.91 |
| Malignant | 2.58±1.78, 2.1 | 136.11±45.09, 119.25 | 772.69±793.20, 547.25 | 1.49±2.66, 0.96 |
| value* | 0.382 | 0.063 | 0.149 | 0.844 |
| * Mann-Whitney U test. NLR – neutrophil to lymphocyte ratio; PLR – platelet-to-lymphocyte ratio; SII – systemic immune inflammation index; SIRI – systemic inflammation response index. | ||||